Earnings Scheduled For May 14, 2025
Insights Ahead: ScPharmaceuticals's Quarterly Earnings
Craig-Hallum Maintains ScPharmaceuticals(SCPH.US) With Buy Rating
Craig-Hallum Reaffirms Their Buy Rating on ScPharmaceuticals (SCPH)
Earnings Preview: SCPH to Report Financial Results Post-market on May 14
Investors Welcome US-UK Trade Talks as US Futures Surge in Thursday's Premarket
ScPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025
ScPharmaceuticals Announces Participation in Three Upcoming Investor Conferences
Analysts Are Bullish on These Healthcare Stocks: ScPharmaceuticals (SCPH), Sarepta Therapeutics (SRPT)
ScPharmaceuticals' Earnings Call Highlights Growth and Challenges
A Quick Look at Today's Ratings for ScPharmaceuticals(SCPH.US), With a Forecast Between $11 to $25
Analyst Expectations For ScPharmaceuticals's Future
Maxim Group Maintains Buy on ScPharmaceuticals, Lowers Price Target to $12
Q4 2024 ScPharmaceuticals Inc Earnings Call
Craig-Hallum Sticks to Its Buy Rating for ScPharmaceuticals (SCPH)
Maxim Adjusts Price Target on ScPharmaceuticals to $12 From $20, Keeps Buy Rating
ScPharmaceuticals Price Target Maintained With a $18.00/Share by HC Wainwright & Co.
ScPharmaceuticals Analyst Ratings
TD Cowen Maintains ScPharmaceuticals(SCPH.US) With Buy Rating, Maintains Target Price $25
Strong Growth Prospects for ScPharmaceuticals: Buy Rating Justified by Furoscix Success and Strategic Expansion